Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1U3EG
|
|||
| Drug Name |
MAb114
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Ebola virus infection [ICD-11: 1D60.0] | Phase 2/3 | [1] | |
| Company |
Ridgeback Biotherapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ebola virus Envelope glycoprotein (EV GP) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03719586) Investigational Therapeutics for the Treatment of People With Ebola Virus Disease. U.S. National Institutes of Health. | |||
| REF 2 | Ansuvimab: First Approval. Drugs. 2021 Apr;81(5):595-598. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.